Development of multi-lateral cancer gene therapy by enhancing anti-tumor activity of inactivated Sendai virus particle

我们报道了紫外线灭活的仙台病毒颗粒（日本包膜血凝病毒；HVJ-E）具有多种抗肿瘤活性。HVJ-E已开始临床应用，以评价该颗粒在癌症患者中的安全性和有效性。为了增强抗肿瘤活性，我们尝试将治疗分子掺入HVJ-E中。因此，含有il - 2或IL-12基因的HVJ-E增强了抗肿瘤免疫。表面含有IL-12多肽的HVJ-E被开发出来，比原始的HVJ-E单独治疗黑色素瘤更有效。加入到HVJ-E中的Rad51 siRNA与抗肿瘤试剂达卡巴嗪联合使用时，增强了肿瘤治疗的效果。

We have reported that UV-inactivated Sendai virus particles (hemagglutinating virus of Japan envelope; HVJ-E) have multiple anti-tumor activities. Clinical application of HVJ-E has been started to evaluate the safety and efficacy of the particle in cancer patients. To enhance the anti-tumor activities, we attempted to incorporate therapeutic molecules into HVJ-E. As a result, HVJ-E containing IL2 or IL-12 gene enhanced anti-tumor immunity. HVJ-E having IL-12 polypeptide on the surface was developed and was more effective for the treatment of melanoma than original HVJ-E alone. Rad51 siRNA incorporated into HVJ-E augmented the effect of cancer treatment when combined with anti-tumor reagent, dacarbazine.